BRISTOL-MYERS SQUIBB COMPANY Excess Tax Benefit from Share-based Compensation, Financing Activities
BRISTOL-MYERS SQUIBB COMPANY (BMY) reported Excess Tax Benefit from Share-based Compensation, Financing Activities of $92.00 million for the 12-month period ending 2016-12-31, per its 10-K filed 2017-02-21.
Discontinued › Notes › Compensation Related Costs
us-gaap:ExcessTaxBenefitFromShareBasedCompensationFinancingActivities · last filed 2017-02-21
- BRISTOL-MYERS SQUIBB COMPANY excess tax benefit from share-based compensation, financing activities for fiscal 2016 was $92.00M, a 37.41% decline from fiscal 2015.
- BRISTOL-MYERS SQUIBB COMPANY excess tax benefit from share-based compensation, financing activities for fiscal 2015 was $147.00M, a 12.21% increase from fiscal 2014.
- BRISTOL-MYERS SQUIBB COMPANY excess tax benefit from share-based compensation, financing activities for fiscal 2014 was $131.00M, a 1.55% increase from fiscal 2013.
- BRISTOL-MYERS SQUIBB COMPANY excess tax benefit from share-based compensation, financing activities for fiscal 2013 was $129.00M, a 81.69% increase from fiscal 2012.
| Period end | Excess Tax Benefit from Share-based Compensation, Financing Activities 12 month |
|---|---|
| 2016-12-31 | $92.00M 10-K · filed 2017-02-21 |
| 2015-12-31 | $147.00M 10-K · filed 2017-02-21 |
| 2014-12-31 | $131.00M 10-K · filed 2017-02-21 |
| 2013-12-31 | $129.00M 10-K · filed 2016-02-12 |
| 2012-12-31 | $71.00M 10-K · filed 2015-02-13 |
| 2011-12-31 | $47.00M 10-K · filed 2014-02-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |